The human genome is organized into multiple structural layers, ranging from chromosome
territories to progressively smaller substructures, such as topologically associating domains …

Abstract Interleukin (IL)-6 is a pro-inflammatory cytokine that is expressed in prostate tumors
and in the stromal tumor micro-enviroment. It is known to regulate proliferation, apoptosis …

Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of
multiple genes including MYC, and supraphysiological androgen is effective in some …

Prostate cancer (PCa) shows strong dependence on the androgen receptor (AR) pathway.
Here, we show that squalene epoxidase (SQLE), an enzyme of the cholesterol biosynthesis …

MYC is a well characterized oncogenic transcription factor in prostate cancer, and CTCF is
the main architectural protein of three-dimensional genome organization. However, the …

Class III β-tubulin (βIII-tubulin) is frequently overexpressed in human tumors and is
associated with resistance to microtubule-targeting agents, tumor aggressiveness, and poor …

Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR
chromatin binding profiles are highly plastic and form recurrent programmatic changes that …

Cancer arises following alterations at different cellular levels, including genetic and
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …

Enzalutamide, an antiandrogen, is approved for therapy of castration resistant prostate
cancer. Clinical applications have shown that approximately 30% of patients acquire …

Long non-coding RNAs (lncRNAs) are emerging as novel diagnostic markers of prostate
cancer (PCa) and new determinants of castration-resistant PCa (CRPC), an aggressive and …